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Background: To evaluate the local response according to stability after radiotherapy (RT) with a special focus on
quality-of-life (QoL), fatigue, pain and emotional distress in patients with unstable spinal bone metastases.
Methods: In this prospective trial, 30 patients were treated from September 2011 until March 2013. The stability
of osteolytic metastases in the thoracic and lumbar spine was evaluated on the basis of the Taneichi-score after
three and six months. EORTC QLQ-BM22, EORTC QLQ-FA13, and QSC-R10 were assessed at baseline, and three
months after RT.
Results: After 3 months, 25% (n = 6) and after 6 months 33.3% (n = 8) were classified as stable. QoL, fatigue,
and emotional distress showed no difference over the course. The pain response 3 months after RT showed a
significant difference (p < 0.001). Pathological fractures occurred in 8.3% of the patients (n = 2) within six months
following RT.
Conclusions: Our trial demonstrated that RT can improve stability in one third of patients over a 6-months period
with unstable spinal metastases. Importantly, for these patients pain relief was detected but RT had no impact on
QoL, fatigue, and emotional distress.
Trial registration: Clinical trial identifier NCT01409720.
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Spinal bone metastases represent the most frequent site
of skeletal metastasis [1]. The effects of bone metastases
are a major clinical concern and result in pain at rest
and during exercise, limitations in daily life, lower perform-
ance ability, risk of pathological fractures and neurologic
deficits [2]. Radiotherapy (RT) is the most common treat-
ment option of bone metastases in advanced tumor disease
[3]. Standard clinical care of unstable metastases often
includes patient immobilization either by means of an
orthopedic thoracic corset or by confining the patient to
bed in order to prevent pathological fractures, which
further decreases patients’ quality-of-life (QoL). Fatigue* Correspondence: harald.rief@med.uni-heidelberg.de
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unless otherwise stated.is one of the most prevalent and distressing symptoms
reported by cancer patients [4]. For these reasons, local
control, and re-ossification of formerly unstable osteolytic
lesions are an important clinical challenge and represent a
goal of any therapy aiming to manage osteolytic bone
metastases. An essential aspect is the stability of the verte-
bral bodies affected. A recent trial showed that the use of
a systematic radiological scoring system to classify osteo-
lytic metastases of the vertebral column was practicable in
daily routine [5].
The effect of palliative RT in patients with unstable
bone metastases is not well analyzed. The aim of this
prospective trial was to evaluate the local response
according to stability after RT with a special focus on
QoL, fatigue, pain and emotional distress in patients
with unstable spinal bone metastases.. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Rief et al. Radiation Oncology 2014, 9:133 Page 2 of 7
http://www.ro-journal.com/content/9/1/133Methods
From September 2011 through March 2013, 30 consecu-
tive patients with a histologically confirmed cancer of any
primary and unstable spinal osteolytic metastases of the
thoracic or lumbar segments were screened and included
at the Radiooncology Department of the Heidelberg
University Clinic. Inclusion criteria were an age of 18 to
80 years, written consent to participate, and already initi-
ated bisphosphonate therapy. The patients were subjected
to a staging of their vertebral column within the context
of the computed tomography (CT) designed to plan the
radiation schedule prior to enrolment into the trial. In this
examination metastases were classified as “stable” or “un-
stable”. Patients with unstable vertebral-body lesions wereFigure 1 Taneichi score.included. The stability of each affected vertebral body was
assessed according to the Taneichi score [6] on the basis
of the CT image recorded before RT and also during
follow-up restaging CT’s three and six months after RT
(Figure 1).
The osteolytic metastases were rated on a scale from
A to F. Subtypes A to C were defined as stable, subtypes
D to F as unstable. In cases in which only one lesion was
rated as unstable in a patient with multiple metastases,
the score was “unstable”. The stability was measured
after twelve weeks, and after six months.
The target parameters of QoL, fatigue, and emotional
distress were assessed at baseline (t0) and twelve weeks
after RT (t2), and comprise the documentation and
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EORTC QLQ-FA13, QSC-R10, and the recording of
patient-specific data. For pain documentation, we used the
visual analog scale. The “bone survival” was defined as
time from initial diagnosis of spinal bone metastases to
death. The start of irradiation of bone metastases was not
equalized to the initial diagnosis of bone metastases. Bone
metastases distant from the irradiated site were not in-
cluded. Overall survival was defined as time from initial
diagnosis of primary site to death. We estimated patient
survival using the Kaplan-Meier survival method. Patients
were censored on the basis of whether they were alive.
The data of the patient records was collected by the
authors. Patient characteristics are shown in Table 1. The
study was approved by the Heidelberg Ethics Committee
(Nr. S-316/2011).Table 1 Patient characteristics at baseline
n %
Age (years)















Mean (range) 2.8 (1–11)
Solitary 13 43.3
Multiple 17 56.7





Surgical corset 16 53.3
Bisphosphonates before RT 28 93.3
Antihormonal therapy before RT 3 10.0
Chemotherapy before RT 20 66.7
Pathological fractures at baseline 4 13.3
SD Standard deviation, RT Radiotherapy.Radiotherapy
RT was performed at the Radiooncology Department of
the Heidelberg University Clinic. After virtual simulation
was performed to plan the radiation schedule, RT was
carried out via one single dorsal photon field using 6
MV photons. Primary target volume (PTV) covered the
specific vertebral body affected as well as the ones imme-
diately above and below. Twenty-five patients (83.3%)
were treated with 10 × 3 Gy, five patients (16.7%) with
20 × 2 Gy. The median individual dose in all patients was
3 Gy (range 2–3 Gy), the median total dose 30 Gy (range
30–40 Gy). The individual and total doses were decided
separately for each individual patient, depending on the
histology, the patient’s general state of health, and on the
current staging and the corresponding prognosis.
Sample calculation and statistical analysis
The total number of patients undergoing RT in the radi-
ation oncology department of the Heidelberg University
Clinic for metastatic processes in the vertebral column
in the recruitment period is approx. 120, about 60 of
whom shall fulfill the inclusion criteria. On account of
the explorative character of this study it was not possible
to estimate the total number of cases; with a scheduled
number of 30 patients, it will, however, be possible to
detect a standardized effect (Cohen’s d) of 0.8 with a
power of 80% and an α significance level of 5%. All
variables were analyzed descriptively by tabulation of the
measures of the empirical distributions. According to the
scale level of the variables, means, and standard deviations
or absolute and relative frequencies, respectively, will be
reported. Descriptive p-values of the corresponding statis-
tical tests comparing the treatment times will be given.
Additionally, for difference between t0 and t2 Wilcoxon
signed rank test was used. The Cohen’s effect (ES) size
was assessed for clinically relevant changes in question-
naires measures (<0.3 low, 0.3-0.7 moderate, >0.7 strong
difference). All statistical analyses were done using SAS
software Version 9.1 (SAS Institute, Cary, NC, USA).
Measures of primary and secondary End points
The primary endpoint was local response and assessed the
stability according to Taneichi-score [6] over the course.
Secondary endpoints were QoL, fatigue, emotional distress,
and pain. QoL, assessed using the EORTC QLQ BM22
questionnaire, which is specially designed for patients with
bone metastases. The QLQ BM22 module (range 0–100)
comprises 22 items and four scales for the measurement of
pain in various parts of the body (painful sites), pain char-
acteristics (persistent pain, recurrent pain), functional im-
pairment (occurrence of pain when performing different
activities, interference with everyday activities), and psy-
chosocial aspects (family, worries, hope) [7]. Fatigue was
assessed using the EORTC QLQ FA13 (range 0–100). This
Table 3 The results of Taneichi Score evaluation
n %
Stability after 3 months
Unstable 18 75.0
Stable 6 25.0
Stability after 6 months
Unstable 16 66.7
Stable 8 33.3
Bone fracture before RT
Yes 4 13.3
No 26 86.7
Bone fracture 6 months after RT
Yes 6 25.0
No 18 75.0
Stability after 3 and 6 months, pathological fracture at baseline and 6 months
after RT.
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measuring cancer-related fatigue [8], with subscales cover-
ing physical fatigue, emotional fatigue, cognitive fatigue,
interference with daily life, and social sequelae. Emotional
distress was assessed using the QSC-R10 (range 0–50)
questionnaire. The QSC-R10 [9] module is a valid and reli-
able questionnaire for determining emotional distress and
anxiety in cancer patients [10]. The questionnaires were
filled out by the patients at the study site. Pain was assessed
according the visual analog scale (0–100).
Results
The median follow-up was 13.2 months. The survival
status at last follow-up showed that 7 patients (23.3%)
were still alive and 23 patients (76.7%) had died from
cancer. Six patients (20.0%) died within the first twelve
weeks following RT, no additional patient died within
6 months due to tumor progression.
The evaluation of the distribution of subtypes A to F
(Table 2) showed a minor change in the direction of
improvement over the course of time. After 3 months,
improvement occurred in 33.3% of the cases (n = 8), no
change was seen in 66.7% (n = 16) of the cases. AfterTable 2 The evaluation of the distribution of subtypes
stable and unstable metastases over the course of time
(0–3 and 0–6 month)
A. Subtypes after 3 months
Subtypes before radiotherapy
A B C D E F Total
A 0 0 0 0 0 0 0
B 0 0 0 0 0 0 0
C 0 0 0 0 0 0 0
D 0 0 2 5 0 0 7
E 0 0 3 2 6 0 11
F 0 0 1 0 0 5 6
Total 0 0 6 7 6 5 24
B. Subtypes after 6 months
Subtypes before radiotherapy
A B C D E F Total
A 0 0 0 0 0 0 0
B 0 0 0 0 0 0 0
C 0 0 0 0 0 0 0
D 0 0 2 5 0 0 7
E 0 1 4 0 6 0 11
F 0 0 1 0 0 5 6
Total 0 1 7 5 6 5 24
This Bowker Test showed the distribution of subtypes of Taneichi-Score before
and 3 months after radiation therapy (A). Asymmetry was apparent (p = 0.238)
and the correlation (kappa = 0.55) was good. The evaluation of the distribution
of subtypes A to F showed a minor change in the direction of improvement
over the course of time. Deterioration occurred in 0% of the cases, improvement
in 33.3% (n = 8). No change was seen in 66.7% (n = 16) of the cases. After 6
months (p = 0.629, kappa = 0.57) the distribution showed the same results
of subtypes.6 months the distribution showed the same results of sub-
types. No deterioration was seen after 3 and 6 months.
This Bowker test shows the distribution pattern of the
subtypes according to Taneichi prior to, three and six
months after RT. Asymmetry was apparent (p = 0.238 and
p = 0.629) and the correlation (kappa = 0.55 and 0.57)
was good (Table 2). According to Taneichi-score, after
3 months 25% (n = 6) and after 6 months, 33.3% (n = 8)
were classified as stable (Table 3).Table 4 Effects of RT on quality of life (EORTC QLQ-BM 22)
Symptom scales n mean SD
Painful sites
baseline (t0) 30 42.00 26.27
3 months (t2) 24 36.67 24.48
Treatment effect (t0-t2) after 3 months p = 0.346
Effect size (t0-t2) after 3 months = 0.21
Pain characteristics
baseline (t0) 30 47.04 33.10
3 months (t2) 24 39.35 34.67
Treatment effect (t0-t2) after 3 months p = 0.172
Effect size (t0-t2) after 3 months = 0.33
Functional interference
baseline (t0) 30 53.06 28.17
3 months (t2) 24 46.18 28.55
Treatment effect (t0-t2) after 3 months p = 0.186
Effect size (t0-t2) after 3 months = 0.26
Psychosocial aspects
baseline (t0) 30 60.19 21.50
3 months (t2) 24 56.48 21.2
Treatment effect (t0-t2) after 3 months p = 0.082
Effect size (t0-t2) after 3 months = 0.34
Table 6 Pain over the course and emotional distress
according to QSC-R10 questionnaire
n mean SD
QSC-R10
baseline (t0) 30 21.90 10,81
3 months (t2) 24 18.88 9,25
Treatment effect (t0-t2) after 3 months p = 0.108
Effect size (t0-t2) after 3 months = 0.29
Visual analog scale
baseline (t0) 30 51.7 20.0
3 months (t2) 24 40.7 22.0
Treatment effect (t0-t2) after 3 months p < 0.001
Effect size (t0-t2) after 3 months = 0.83
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FA13, and emotional distress according to the QSC-R10,
no difference was seen after 3 months (Tables 4, 5, 6). The
pain response 3 months after RT showed a significant dif-
ference (P < 0.001, ES 0.83) (Table 6).
A pathological fracture was diagnosed in 4 patients
(13.3%) prior to RT. Fractures occurred in 8.3% of the pa-
tients (n = 2) within six months following RT (Table 3).
These data correspond to a six-months overall survival
of 93.3%, a one-year survival of 76.7%, and a two-year
survival of 45.8% (Figure 2A). The “bone survival” was
66.7% at six months, 53.3% at one year, and 26.6% at two
years (Figure 2B).
Discussion
Bone metastases frequently occur in advanced cancer
diseases, and the majority of cases are localized in the
spinal column. Re-calcification of unstable lesions is one
of the main goals of palliative RT. Patients affected are
in most cases immobilized, primarily due to the risk of
pathological fracture and the associated risk of spinal
cord compression. An early identification of osteolyticTable 5 Effects of RT on fatigue (EORTC QLQ-FA 13)
Symptom scales n mean SD
Physical fatigue
baseline (t0) 30 55.00 32.06
3 months (t2) 24 51.39 31.63
Treatment effect (t0-t2) after 3 months p = 0.534
Effect size (t0-t2) after 3 months = 0.04
Emotional fatigue
baseline (t0) 30 36.94 30.14
3 months (t2) 24 29.17 30.00
Treatment effect (t0-t2) after 3 months p = 0.616
Effect size (t0-t2) after 3 months = 0.12
Cognitive fatigue
baseline (t0) 30 21.48 25.59
3 months (t2) 24 20.83 24.37
Treatment effect (t0-t2) after 3 months p = 0.304
Effect size (t0-t2) after 3 months = 0.23
Interference with daily life
baseline (t0) 30 50.19 31.70
3 months (t2) 24 48.47 30.21
Treatment effect (t0-t2) after 3 months p = 0.563
Effect size (t0-t2) after 3 months = 0.10
Social sequelae
baseline (t0) 30 54.19 51.50
3 months (t2) 24 52.48 50.21
Treatment effect (t0-t2) after 3 months p = 0.583
Effect size (t0-t2) after 3 months = 0.11metastases and their classification in terms of stability is
a major factor in the decision for the therapeutical mea-
sures to be taken. The scoring system according to
Taneichi [6] constitutes a simple method for classifying
the vertebral bodies as “stable” or “unstable”, which is
why this score is employed in this evaluation. Here, weFigure 2 A. Overall survival, B. Bone survival. The numbers of
patients at risk are mentioned above the time in months.
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calcification in 25% and 33% of patients after 3 and
6 months, respectively. Rief et al. [5] described the the-
rapeutic response of osteolytic spinal lesions in lung
cancer following RT. Of the 123 patients in whom the
metastases were classified unstable prior to radiotherapy,
21 patients (17%) were classified stable after three months,
and 30 patients (24%) stable after six months. Our calcula-
tion was higher due to different histologies and smaller
sample size. However, RT and consecutive re-calcification
of the lesions made it possible to classify 33.3% of the
originally unstable osteolytic processes as stable after six
months. Our results showed a pathological fracture in
13.3% of the vertebral bodies prior to RT. Other patho-
logical fractures up to six months in the further course
were seen only in 2 cases (8.3%). In previous retrospective
studies among American and Japanese populations, the
incidence of pathologic fractures in the vertebral column
is given at 10% [11,12] and was comparable with our data.
No substantial improvement with small to moderate
effect sizes was observed in all dimensions of the EORTC
QLQ-BM 22 (painful sites, pain characteristics, functional
interference, and psychosocial aspects) after three and six
months. With a high rate of local response and stability
due to RT, patients with unstable metastases would benefit
from RT. Through the low local response and small
sample size, we were not able to show any difference in
QoL. Lam et al. showed that baseline KPS, age, and em-
ployment status had significant impacts in self-reported
HRQOL in patients with bone metastases receiving pallia-
tive RT [13]. However, we could not show predictive
factors due to our small sample size. Fatigue (EORTC
QLQ-FA13), and emotional distress (QSC-R10) showed
no statistical significance between baseline and after
3 months as well. Cancer-related fatigue is defined as a
persistent subjective sensation of tiredness relating to
cancer treatment that impairs the patients’ physical and
mental performance [14]. It is of great clinical relevance
for patients in an advanced stage of cancer disease [15].
RT determined a therapy effect in pain: the pain score
after three months was smaller (p < 0.001, ES 0.83) than at
baseline. Palliative RT is an established effective modality
for the treatment of pain in patients with bone metastases
of the spinal column [16,17] and will continue to remain
the principal option for the treatment of painful bone
metastases [18].
The survival of patients with bone metastases is still
poor. In a recent study, Rief et al. [19] showed that the
stability of the vertebral bodies played no role with regard
to survival. Our results underlined the very low survival
times in patients with unstable metastases.
Limitations of the study are the relatively small sample
size, the variety of primary tumors and patient conditions,
and the exclusion of patients presenting with cervicalspine metastases. Questionnaires were only provided at
baseline and 3 months after RT - as this time period was
believed to be sufficient to demonstrate clinical changes.
We lack systematic knowledge of possible further im-
provement after 6 and 12 months. Among the strengths
of the study are the prospective setting, the use of a scor-
ing system for stability of bone metastases and standard-
ized and specific measures to assess multiple domains of
QoL among patients with unstable bone metastases.
Conclusion
In this group of patients with unstable bone metastases
we were able to show that RT can improve stability in
one-third of patients over a 6-months period. Importantly,
these patients showed a pain response after 3 months, but
RT alone is not sufficient enough to improve QoL and
fatigue, and reduce emotional distress and anxiety specific
to patients suffering from spinal metastases. Large con-
trolled trials are necessary to confirm these findings.
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